Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals, Inc. (ICPT) and Encourages Investors to Contact the Firm

NEW YORK--()--Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) securities between May 31, 2016 and September 20, 2017 (the “Class Period”). Investors have until November 27, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The Complaint alleges that, throughout the Class Period, Intercept made materially false and/or misleading statements and/or failed to disclose that its lead product candidate, Ocaliva, had undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis ("PBC"). As a result, the Company's public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC. Following this news, Intercept’s share price fell $15.36 per share, or 13.53%, to close at $98.12 per share on September 12, 2017.

On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled "FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease," warning doctors after reports of multiple deaths linked to the drug. Following this news, Intercept’s share price fell $24.42 per share, or 24.88%, to close at $73.70 per share on September 21, 2017.

If you purchased or otherwise acquired Intercept securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Intercept Pharmaceuticals lawsuit, please go to http://www.bespc.com/icpt. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
212-355-4648
investigations@bespc.com
www.bespc.com

Release Summary

Bragar Eagel & Squire PC Announces Filing of Class Action Lawsuit Against Intercept Pharmaceuticals (ICPT) and Encourages Investors to Contact Firm

$Cashtags

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
212-355-4648
investigations@bespc.com
www.bespc.com